Stockscreener 앱 받기
0.5472
3.21%
0.017
시간 외 거래:
.54
-0.0072
-1.32%
전일 마감가:
$0.5302
열려 있는:
$0.525
하루 거래량:
4.59M
Relative Volume:
0.82
시가총액:
$165.10M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.7296
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
+5.23%
1개월 성능:
+3.25%
6개월 성능:
-37.46%
1년 성능:
-27.17%
1일 변동 폭
$0.52
$0.5589
1주일 범위
$0.47
$0.5589
52주 변동 폭
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5472 | 159.97M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Evaluating Sangamo Therapeutics Inc. with trendline analysisJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - Newser
Is Sangamo Therapeutics Inc. undervalued by DCF analysisGlobal Markets & Weekly High Return Opportunities - خودرو بانک
Will Sangamo Therapeutics Inc. benefit from current market trends2025 Market Outlook & AI Based Buy and Sell Signals - خودرو بانک
Comparing Sangamo Therapeutics Inc. in custom built stock radarsJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser
Can Sangamo Therapeutics Inc. stock outperform in a bear marketProfit Target & Long-Term Safe Investment Plans - خودرو بانک
Custom strategy builders for tracking Sangamo Therapeutics Inc.July 2025 Drop Watch & Low Drawdown Trading Techniques - Newser
Is Sangamo Therapeutics Inc. benefiting from interest rate changesPortfolio Value Report & Real-Time Market Sentiment Reports - خودرو بانک
Risk adjusted return profile for Sangamo Therapeutics Inc. analyzedJuly 2025 Opening Moves & Stock Market Timing Techniques - Newser
Sangamo Therapeutics: A High-Conviction Biotech Play with a Clear Path to FDA Approval in 2026 - AInvest
Sangamo reports promising data for Fabry disease gene therapy - Investing.com
Sangamo Biosciences Reveals Promising Fabry Disease Study Results - TipRanks
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - The Manila Times
1.97 mL/min Kidney Function Improvement: Sangamo's One-Time Gene Therapy Could Transform Fabry Disease Care - Stock Titan
Will Sangamo Therapeutics Inc. stock recover after recent dropJuly 2025 Decliners & Verified Swing Trading Watchlists - Newser
Chart based analysis of Sangamo Therapeutics Inc. trendsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
Published on: 2025-09-04 02:16:59 - Newser
Will Sangamo Therapeutics Inc. outperform its industry peers2025 Price Momentum & Free Expert Verified Stock Movement Alerts - خودرو بانک
Measuring Sangamo Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
What the charts say about Sangamo Therapeutics Inc. todayFed Meeting & Low Drawdown Trading Techniques - Newser
What are Sangamo Therapeutics Inc.’s recent SEC filings showingJuly 2025 Big Picture & Short-Term High Return Strategies - خودرو بانک
Smart tools for monitoring Sangamo Therapeutics Inc.’s price actionEarnings Overview Summary & Smart Money Movement Alerts - Newser
What’s the profit margin of Sangamo Therapeutics Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - خودرو بانک
What MACD signals say about Sangamo Therapeutics Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
What institutional flow reveals about Sangamo Therapeutics Inc.Bull Run & Weekly High Potential Stock Alerts - Newser
Analyzing Sangamo Therapeutics Inc. with risk reward ratio charts2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Real time breakdown of Sangamo Therapeutics Inc. stock performance2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
Should I buy Sangamo Therapeutics Inc. stock now2025 Biggest Moves & Daily Growth Stock Investment Tips - خودرو بانک
Sangamo Therapeutics Inc.’s volatility index tracking explainedTrade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Is Sangamo Therapeutics Inc.’s ROE strong enough2025 Growth vs Value & Weekly Breakout Watchlists - خودرو بانک
Should you hold or exit Sangamo Therapeutics Inc. nowLayoff News & Risk Controlled Stock Pick Alerts - Newser
Sangamo Therapeutics Inc. stock trend outlook and recovery pathEarnings Growth Summary & Real-Time Chart Breakout Alerts - Newser
Technical analysis overview for Sangamo Therapeutics Inc. stock2025 Stock Rankings & Consistent Profit Alerts - Newser
Will Sangamo Therapeutics Inc. bounce back from current support2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Sangamo Therapeutics Inc. benefiting from innovation trendsJuly 2025 Patterns & Fast Exit and Entry Trade Guides - خودرو بانک
Is Sangamo Therapeutics Inc. a cyclical or defensive stockPortfolio Profit Report & Community Verified Watchlist Alerts - خودرو بانک
CEO Moves: Should I buy Sangamo Therapeutics Inc. stock now2025 Risk Factors & Weekly Stock Breakout Alerts - خودرو بانک
Does Sangamo Therapeutics Inc. fit your quant trading modelWeekly Trade Report & Weekly Hot Stock Watchlists - Newser
What is Sangamo Therapeutics Inc.’s valuation compared to sectorJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - خودرو بانک
Analyzing Sangamo Therapeutics Inc. with multi timeframe chartsInflation Watch & Real-Time Buy Signal Alerts - Newser
Developing predictive dashboards with Sangamo Therapeutics Inc. data2025 Risk Factors & Growth-Oriented Investment Plans - Newser
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):